» Articles » PMID: 35865518

The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance

Overview
Journal Front Immunol
Date 2022 Jul 22
PMID 35865518
Authors
Affiliations
Soon will be listed here.
Abstract

Signal transducer and activator of transcription 3 (STAT3) is a member of the Janus kinase (JAK)-STAT pathway, which is one of the key pathways contributing to cancer. STAT3 regulates transcription downstream of many cytokines including interleukin (IL)-6 and IL-10. In cancer, STAT3 is mainly described as a tumor promoter driving tumor cell proliferation, resistance to apoptosis, angiogenesis and metastasis and aberrant activation of STAT3 is associated with poor prognosis. STAT3 is also an important driver of immune evasion. Among many other immunosuppressive mechanisms, STAT3 aids tumor cells to escape natural killer (NK) cell-mediated immune surveillance. NK cells are innate lymphocytes, which can directly kill malignant cells but also regulate adaptive immune responses and contribute to the composition of the tumor microenvironment. The inborn ability to lyse transformed cells renders NK cells an attractive tool for cancer immunotherapy. Here, we provide an overview of the role of STAT3 in the dynamic interplay between NK cells and tumor cells. On the one hand, we summarize the current knowledge on how tumor cell-intrinsic STAT3 drives the evasion from NK cells. On the other hand, we describe the multiple functions of STAT3 in regulating NK-cell cytotoxicity, cytokine production and their anti-tumor responses . In light of the ongoing research on STAT3 inhibitors, we also discuss how targeting STAT3 would affect the two arms of STAT3-dependent regulation of NK cell-mediated anti-tumor immunity. Understanding the complexity of this interplay in the tumor microenvironment is crucial for future implementation of NK cell-based immunotherapies.

Citing Articles

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.

Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K Front Immunol. 2024; 15:1442673.

PMID: 39234249 PMC: 11371580. DOI: 10.3389/fimmu.2024.1442673.


The anticancer mechanisms of rhoptry protein 16 on lung adenocarcinoma cells.

Li G, Li Q, Tong Y, Zeng J, Dang T, Yang N Cancer Biol Ther. 2024; 25(1):2392902.

PMID: 39174877 PMC: 11346528. DOI: 10.1080/15384047.2024.2392902.


In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.

Pesini C, Artal L, Paul Bernal J, Sanchez Martinez D, Pardo J, Ramirez-Labrada A Oncoimmunology. 2024; 13(1):2379062.

PMID: 39036370 PMC: 11259085. DOI: 10.1080/2162402X.2024.2379062.


STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance.

Witalisz-Siepracka A, Denk C, Zdarsky B, Hofmann L, Edtmayer S, Harm T Front Immunol. 2024; 15:1374068.

PMID: 39034990 PMC: 11257888. DOI: 10.3389/fimmu.2024.1374068.


Plasma Gelsolin Inhibits Natural Killer Cell Function and Confers Chemoresistance in Epithelial Ovarian Cancer.

Onuma T, Asare-Werehene M, Fujita Y, Yoshida Y, Tsang B Cells. 2024; 13(11.

PMID: 38891037 PMC: 11171658. DOI: 10.3390/cells13110905.


References
1.
Gotthardt D, Putz E, Straka E, Kudweis P, Biaggio M, Poli V . Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014; 124(15):2370-9. DOI: 10.1182/blood-2014-03-564450. View

2.
Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

3.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B . Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003; 198(4):557-67. PMC: 2194180. DOI: 10.1084/jem.20030788. View

4.
Koch J, Steinle A, Watzl C, Mandelboim O . Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013; 34(4):182-91. DOI: 10.1016/j.it.2013.01.003. View

5.
Poggi A, Zocchi M . Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Mol Ther Oncolytics. 2022; 24:26-42. PMC: 8693432. DOI: 10.1016/j.omto.2021.11.016. View